East Kent Hospitals University Nhs Foundation Trust

Annexon's ANX007 Shows Promise in Protecting Vision in Geographic Atrophy

8 months ago

• Annexon will present Phase 2 ARCHER trial data on ANX007 for geographic atrophy (GA) at upcoming Retina Society and Euretina Congress meetings. • ANX007 demonstrated significant vision protection in standard and low light conditions, along with preservation of photoreceptors in the fovea. • The ARCHER II Phase 3 pivotal program is underway, with data expected in the second half of 2026, evaluating ANX007's potential to protect vision in GA. • ANX007 is a first-in-kind Fab designed to block C1q locally in the eye, potentially transforming the GA treatment landscape.